Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...
April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- DualityBio granted BioNTech exclusive, worldwide rights, excluding China, Hong Kong, and Macau, to develop and commercialize DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.
- DualityBio has the option to co-develop and co-promote DB-1311 in the U.S. with cost and profit/loss sharing.
- DualityBio will receive $170M up front and is eligible for up $1.5B in development, regulatory, and sales milestones, plus single-digit to double-digit tiered royalties.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
We are tracking the biopharma R&D partnerships in neurology through the first half of 2023. Some notable licensing deals include Voyager's partnership with Neurocrine, which secured an upfront payment of $175 million and the potential to achieve up to $4.2 billion...